RxDoctor Payments Data

Danny Eapen, MD

Cardiovascular Disease · Houston, TXNPI 1154505238

Payments from drug & device makers

$16,150in general payments, 2019–2025

Across 21 payments — averaging $769.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ionis Pharmaceuticals, Inc.$13K
  • Amarin Pharma, Inc.$3K
  • Inspire Medical Systems, Inc.$137
  • Agepha Pharma FZ LLC$100
  • Novartis$43
  • Boehringer Ingelheim$27
  • plus $87 from 4 others

What the payments were for

  • Consulting fees$11,38370%
  • Speaking & faculty fees$2,64016%
  • Travel & lodging$1,54610%
  • Food & beverage$5824%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,150 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$216,178
Medicare patients
1,465
Services billed
3,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban428$481,714
XareltoRivaroxaban104$112,500
Repatha SureclickEvolocumab103$103,690
JardianceEmpagliflozin74$86,730
EntrestoSacubitril/Valsartan23$40,188
OzempicSemaglutide38$37,631
Praluent PenAlirocumab32$25,627
Repatha SyringeEvolocumab34$24,116
Enoxaparin Sodium38$8,987
Ezetimibe267$7,207
Warfarin Sodium489$5,053
Metoprolol Succinate284$4,592
Rosuvastatin Calcium303$3,184
Atorvastatin Calcium404$3,156
Losartan Potassium292$2,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$27$86,73074 claims
NovartisEntresto$43$40,18823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →